Business Wire

NY-PYRAMID-ANALYTICS

30.11.2022 09:01:54 CET | Business Wire | Press release

Share
Pyramid Analytics Signs More UKI Channel Deals

Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, continues to consistently execute on its strategy to rapidly expand channel partnerships with complementary technology companies, independent software vendors (ISV), consulting firms, value-added resellers (VAR) and systems integrators (SI) across the United Kingdom and Ireland (UKI). The London-based software company today announced new partnerships with Datazed Associates, Data Reply, and Digital Data Consultancy.

Key Points:

  • Pyramid Analytics signed deals with new partners serving the IT needs of mid-size and large enterprises across the UKI: Datazed Associates (Referral Partner); Digital Data Consultancy (Systems Integrator); and Data Reply (Consultancy, Systems Integrator).
  • The channel partner programme is the backbone of Pyramid’s UKI operations, accounting for a significant segment of UK revenue.
  • Pyramid Analytics is recognized for channel excellence. The company was a CRN Channel Awards 2022 finalist.
  • To learn more about becoming a Pyramid partner in the UK and Ireland, contact Bill Clayton, Vice President, Global Partnerships, at bill.clayton@pyramidanalytics.com.

Meet Pyramid Analytics’ New Partners
Datazed Associates is a boutique data consultancy specialising in data governance and data quality. The company’s network of experienced professionals has a strong track record in the insurance industry, having supported general insurers, Lloyd’s market firms, brokers and reinsurers.

Data Reply is the Reply group company offering a broad range of advanced analytics and AI-powered data services. Data Reply operates across industries and business functions to achieve meaningful outcomes through effective use of data.

Digital Data Consultancy provides consulting services in the areas of data management, data science, and digital experience. The company helps clients in retail, hospitality, healthcare, banking and consumer goods to master and reimagine their data, create new value, and differentiate and profit in the digital economy.

Pyramid Analytics Delivers Value for Partners
Partnerships are critical to Pyramid’s ability to scale growth. In turn, partners get access to the Pyramid Decision Intelligence Platform, an innovative augmented analytics platform which has garnered analyst accolades for its ability to transform businesses.

Pyramid Partners benefit from a range of resources to help them effectively market, sell, and deliver the Pyramid Platform, integrated solutions, and services. These include the Pyramid Partner Portal, a one-stop shop for deal management, market education content, co-branded marketing materials, and interactive tools and resources; and the Pyramid Learning Hub for self-guided and expert-led courses, and Pyramid Partner Certification programs.

United Kingdom the World’s “Next Silicon Valley”?
Jeremy Hunt, the UK’s Chancellor of the Exchequer, outlined a number of priorities in his Autumn Statement on 17 November. These included his plan to “turn the United Kingdom into the world’s next Silicon Valley.” Pyramid Analytics has operated and flourished in the UK for nearly five years and are proud of the company’s contribution to achieving this goal. The advanced analytics platform company has added three executives and numerous business development roles in its London office in 2022.

2022 has been momentous for Pyramid Analytics in the UKI:

  • Pyramid executives, customers, partners, media and technology industry analysts celebrated a $120 million Series E funding round at a special event at Tower Bridge in May.
  • Tom Warren, a veteran technology professional and former professional rugby player, was appointed Managing Director for the company’s UKI operations.
  • Bill Clayton joined Pyramid in the new role of Vice President, Global Partnerships. He has more than 20 years of enterprise software experience. Clayton has held positions with global technology leaders including IBM and Oracle. He lives in the UK.
  • Hayley Munro was appointed Vice President of Global Customer Success. This newly created role provides unified, company-wide management of this critical function under one executive. She lives in the UK.

Decision Intelligence is the Next Big Data Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.

The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.

Quotes
Bill Clayton, Vice President of Global Partner Sales, Pyramid Analytics: “Channel partnerships are an essential cornerstone of Pyramid’s growth strategy. Our highly productive and effective work with channel partners has forged a host of mutually beneficial relationships that have driven growth for all involved across the UKI. Channel partners are at the core of Pyramid’s business model. The growth and expansion of the company is firmly embedded with our channel partners.”

About Pyramid Analytics
Pyramid is what’s next in analytics. The award-winning Pyramid Decision Intelligence Platform delivers insights for faster, optimized decisions by providing direct access to any data, enabling governed self-service for any person, and meeting any analytics need in a no-code environment. The Pyramid Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. This enables a strategic, enterprise-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.

Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221130005245/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye